

Appendix 5 (as submitted by the authors): Cost-effectiveness results for treatment pattern changed for IFN-Free DAAs							
		<u>Compared to Common baseline (No Screening)</u>					
<u>Age range</u>	<u>Strategy</u>	<u>Cost</u>	<u>QALYs</u>	<u>ΔCost</u>	<u>ΔQALYs</u>	<u>ICER</u>	<u>Sequential ICER</u>
25-64	No screening	\$71,330	13.7662	-	-	-	-
	Screen & treat with PR	\$71,460	13.7710	\$130	0.0048	\$27,077	\$27,077*
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$71,665	13.7780	\$335	0.0118	\$28,459	\$28,459
	Screen & treat with G1:simeprevir+PR G2/3: SOF/RBV G4/5/6: PR	\$71,666	13.7758	\$336	0.0096	\$34,840	Dominated
45-64	No screening	\$83,335	12.1027	-	-	-	-
	Screen & treat with PR	\$83,342	12.1037	\$152	0.0059	\$25,715	\$25,715
	Screen & treat with G1:simeprevir+PR G2/3: SOF/RBV G4/5/6: PR	\$83,494	12.1097	\$432	0.0114	\$37,882	\$50,953*
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$83,775	12.1152	\$434	0.0142	\$30,462	\$33,831
G1: genotype 1; G2/3: genotype 2 or 3; G4/5/6: genotype 4 or 5 or 6; PR = pegylated interferon plus ribavirin; QALY = quality-adjusted life-year; SIM = simeprevir; SOF/RBV = sofosbuvir plus ribavirin; IFN-Free DAA = interferon-free direct-acting antiviral agents; ICER = incremental cost-effectiveness ratio *Extendedly dominated = the combination of two other alternatives dominated the treatment.							